Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis

Table 1 Summary data of the original studies

Author	Country	Year	Type of study	Patients	Control	Cut off (pmol/L)	TP	FP	FN	TN	SEN	SPE
Moore RG et al. [5]	USA	2008	prospective/retrospective	171	156	/	78	8	93	148	46	95
Zanotti L et al. [6]	Italy	2012	retrospective	193(152 + 41)	125	51	152	19	41	106	79	85
						64	127	6	66	119	66	95
Angioli R et al. [7]	Italy	2013	prospective	101(95 + 6)	103	70	60	0	41	103	59	100
						150	36	0	65	103	36	100
Omer Bet al. [8]	Turkey	2013	prospective l	64(54 + 10)	94(60 + 34)	60	48	32	16	62	75	66
Bignotti E et al. [9]	Italy	2011	prospective	138(109 + 29)	76	/	92	4	46	72	67	95
Zhang, Ai-min et al. [10]	China	2012	prospective	124	206(97 + 109)	/	51	10	73	196	41	95
Total				791	760

Studies [6], [7], [8] and [9] included patients with different pathological types. The pathological types of patients in study [5] and study [10] are unclear. Studies [8] and [10] included people with uterine benign disease and had healthy people as controls. The controls of other studies are healthy.
FN, False Negative; FP, False Positive; SEN, Sensitivity; SPE, Specificity TN, True Negative; TP, True Positive.

ISSN: 1477-7819